CyFlow™ CD26 FITC
| Alternative Name: | ADABP , ADCP2, CD26, DPPIV, TP103 |
| Antibody: | Yes |
| Antigen: | CD26 |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | BA5b |
| Emission Maximum: | 518 nm |
| Excitation Maximum: | 490 to 495 nm |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | FITC |
| Isotype: | IgG2a |
| Laser: | Blue |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | BE480793 |
For Research Use Only
| HLDA Workshop | HLDA VI—WS Code N-L078 |
| Quantity | 100 tests |
| Volume | 2.0 mL |
| Immunogen | A human T cell clone |
| Background Information | CD26 (DPP-IV; dipeptidyl peptidase IV) is a homodimeric cell surface serine peptidase that degradates IFN-γ-induced cytokines, acts as a T cell costimulatory molecule, and participates in multiple immunopathological roles in leukocyte homing and inflammation. Alterations in its peptidase activity are characteristic of malignant transformation. The enzymatic activity increases dramatically with tumor grade and severity. CD26 is expressed in various blood cell types, but also e.g. in cells that are histogenetically related to activated fibroblasts. Alterations in CD26 density have been reported on circulating monocytes and CD4+ T cells during rheumatoid arthritis and systemic lupus erythematosus. |
| Usage | The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests. |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J Clin Pathol. 1993 Apr; 46(4):334‑6. < PMID: 7684403 > | Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland Publishing Inc, New York. 1997; 1‑1342. < NLM ID: 9712219 > | Ellingsen T, Hornung N, Møller BK, Hjelm-Poulsen J, Stengaard-Pedersen K: In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand J Immunol. 2007 Oct; 66(4):451‑7. < PMID: 17850590 > | Stremenova J, Krepela E, Mares V, Trim J, Dbaly V, Marek J, Vanickova Z, Lisa V, Yea C, Sedo A: Expression and enzymatic activity of dipeptidyl peptidase‑IV in human astrocytic tumours are associated with tumour grade. Int J Oncol. 2007 Oct; 31(4):785‑92. < PMID: 17786309 > | Kotacková L, Baláziová E, Sedo A: Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer. Folia Biol (Praha). 2009; 55(3):77‑84. < PMID: 19545486 > | Wong PT, Wong CK, Tam LS, Li EK, Chen DP, Lam CW: Decreased expression of T lymphocyte co‑stimulatory molecule CD26 on invariat natural killer T cells in systemic lupus erythematosus. Immunol Invest. 2009; 38(5):350‑64. < PMID: 19811413 > | Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, Itoi E, Kokubun S: Histogenesis‑specific expression of fibroblast activation proteinand dipeptidylpeptidase‑IV in human bone and soft tissue tumours. Histopathology. 2009 Oct; 55(4):432‑40. < PMID: 19817894 >